Pangen Signs Supply Agreement for Biosimilar Panfotin Products Worth 600 Million KRW
[Asia Economy Reporter Geum Boryeong] PanGen announced on the 12th that it has signed a supply contract for the biosimilar EPO (Panfotin) product with Jungheon Pharmaceutical worth 5,848,014,455 KRW.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
The contract amount corresponds to 10.29% of the sales revenue based on 2018. The contract end date is July 31.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
